"10.1371_journal.pone.0128757","plos one","2015-06-19T00:00:00Z","Peter S Fenwick; Patricia Macedo; Iain C Kilty; Peter J Barnes; Louise E Donnelly","Airway Disease, National Heart and Lung Institute, Imperial College London, London, United Kingdom; Pfizer Inc, Cambridge, Massachusetts, United States of America","Conceived and designed the experiments: ICK PJB LED. Performed the experiments: PSF PM. Analyzed the data: PSF PM LED. Contributed reagents/materials/analysis tools: ICK. Wrote the paper: PSF PM ICK PJB LED.","ICK is an employee of Pfizer lnc; PJB has served on Scientific Advisory Boards of AstraZeneca, Boehringer-Ingelheim, Chiesi, Daiichi-Sankyo, GlaxoSmithKline, Glenmark, Johnson & Johnson, Merck, Novartis, Takeda, Pfizer, Prosonix, RespiVert, Sun Pharmaceuticals, Teva and UCB and has received research funding from Aquinox Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Chiesi, Daiichi-Sankyo, GSK, Novartis,Takeda, Pfizer, Sun Pharmaceuticals. He is also a cofounder of RespiVert (now part of Johnson & Johnson), which has discovered novel inhaled anti-inflammatory treatments for asthma and COPD; LED has received unrestricted research funding from Pfizer Inc, Takeda, Cempra Inc. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","06","Peter S Fenwick","PSF",5,TRUE,3,2,3,5,TRUE,TRUE,FALSE,0,NA,FALSE
